KKR, a global investment firm, has acquired Immedica Pharma, a Stockholm-based pharmaceutical company specializing in rare diseases and specialty care products. The acquisition will involve the reinvestment of Immedica’s existing owner, Impilo, which will become an equal owner alongside KKR. The partnership aims to support Immedica’s continued growth, including the launch of its recently approved ultra-orphan drug Loargys, additional pipeline assets, and continued in-licensing and mergers and acquisitions.